生物制药公司 Adcytherix 专门研究下一代抗体药物偶联物，该公司从顶级投资者那里获得了 3000 万欧元的种子资金。 Biopharmaceutical company Adcytherix, specializing in next-gen antibody drug conjugates, launched with €30M seed funding from top-tier investors.
Adcytherix 是一家生物制药公司，专门研究用于治疗癌症等尚未得到满足的疾病的下一代抗体药物偶联物 (ADC)，该公司以 3000 万欧元的种子资金成立。 Adcytherix, a biopharmaceutical company specializing in next-gen antibody drug conjugates (ADCs) for high unmet need diseases like cancer, launched with €30M seed funding. 该公司由 Emergence Therapeutics 团队创立，并获得了 Pontifax、Pureos Bioventures、RA Capital Management 和 KKR 控制的 Dawn Biopharma 等顶级投资者的支持。 Founded by the Emergence Therapeutics team, it's backed by top-tier investors including Pontifax, Pureos Bioventures, RA Capital Management, and KKR-controlled Dawn Biopharma. 该公司的目标是成为领先的 ADC 开发商。 The company aims to establish itself as a leading ADC developer.